The U.S. Food and Drug Administration (FDA) has expanded the approvals of two Vertex Pharmaceuticals therapies to include additional mutations that cause cystic fibrosis (CF), allowing more people with the condition to become eligible for treatment. The decision concerns Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) and Trikafta (elexacaftor/tezacaftor/ivacaftor). These are CFTR…